TOP TEN perturbations for 38766_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38766_at
Selected probe(set): 38766_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38766_at (38766_at) across 6674 perturbations tested by GENEVESTIGATOR:

cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.2789078
Number of Samples:4 / 4
Experimental cicloheximide study 1
MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:---
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

estradiol; cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):1.9269524
Number of Samples:4 / 4
Experimental estradiol; cicloheximide study 1
MCF7 breast cancer cells were treated with cicloheximide (10 ug/ml) for 1 hour before hormonal treatment with 17{beta}-estradiol (E2, 25 nM) for 24 hours. ATC code:
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

lactic acidosis study 1 / control media treated MCF-7 cell sample

Relative Expression (log2-ratio):1.7451925
Number of Samples:5 / 5
Experimental lactic acidosis study 1
MCF-7 breast cancer cells exposed to lactic acidosis for 4 hour. Cells were serum starved for 24 hours before exposure to lactic acidosis conditions, that were created with the addition of 25mM lactic acid.
Control control media treated MCF-7 cell sample
MCF-7 breast cancer cells treated with control media for 4 hours. Cells were serum starved for 24 hours before treatment with control media (DMEM with 4.5 g/L glucose, supplemented with 10% fetal bovine serum, 1× non-essential amino acid and 1× antibiotics (penicillin, 10000UI/ml; streptomycin, 10000UI/ml).

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.5003347
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

TNF-α;TGF-β study 1 (3D) / untreated A549 cell sample (3D)

Relative Expression (log2-ratio):1.464612
Number of Samples:2 / 2
Experimental TNF-α;TGF-β study 1 (3D)
A549 cells were grown as 3D-culture/spheroids to 80% confluency and incubated with 10 ng/mL TNF and 2 ng/mL TGF two times each for 48 hours. Samples were taken 4 days after the treatment.
Control untreated A549 cell sample (3D)
A549 cells were grown as 3D-culture to 80% confluency and kept in culture for 4 days.

MCF-7:2A / MCF-7

Relative Expression (log2-ratio):-1.456748
Number of Samples:4 / 4
Experimental MCF-7:2A
Long-term estrogen deprived breast cancer cells MCF-7, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. MCF-7 is human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Parental cell line:: MCF-7 Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

MCF-7.5C / MCF-7

Relative Expression (log2-ratio):-1.3550911
Number of Samples:3 / 4
Experimental MCF-7.5C
Human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Long-term estrogen deprived breast cancer cells, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. Parental cell line:: MCF-7 Synonyms:MCF-7 clone 5C; 5C; MCF-7:5C Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):-1.328435
Number of Samples:5 / 17
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons.

DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) / DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)

Relative Expression (log2-ratio):1.253808
Number of Samples:55 / 39
Experimental DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.

DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):-1.2512732
Number of Samples:16 / 33
Experimental DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.

Organism: Homo sapiens
Gene: 38766_at
Selected probe(set): 38766_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38766_at (38766_at) across 6674 perturbations tested by GENEVESTIGATOR:

cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):2.2789078
Number of Samples:4 / 4
Experimental cicloheximide study 1
MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:---
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

estradiol; cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample

Relative Expression (log2-ratio):1.9269524
Number of Samples:4 / 4
Experimental estradiol; cicloheximide study 1
MCF7 breast cancer cells were treated with cicloheximide (10 ug/ml) for 1 hour before hormonal treatment with 17{beta}-estradiol (E2, 25 nM) for 24 hours. ATC code:
Control vehicle (DMSO) treated MCF-7 cell sample
MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h.

lactic acidosis study 1 / control media treated MCF-7 cell sample

Relative Expression (log2-ratio):1.7451925
Number of Samples:5 / 5
Experimental lactic acidosis study 1
MCF-7 breast cancer cells exposed to lactic acidosis for 4 hour. Cells were serum starved for 24 hours before exposure to lactic acidosis conditions, that were created with the addition of 25mM lactic acid.
Control control media treated MCF-7 cell sample
MCF-7 breast cancer cells treated with control media for 4 hours. Cells were serum starved for 24 hours before treatment with control media (DMEM with 4.5 g/L glucose, supplemented with 10% fetal bovine serum, 1× non-essential amino acid and 1× antibiotics (penicillin, 10000UI/ml; streptomycin, 10000UI/ml).

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.5003347
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

TNF-α;TGF-β study 1 (3D) / untreated A549 cell sample (3D)

Relative Expression (log2-ratio):1.464612
Number of Samples:2 / 2
Experimental TNF-α;TGF-β study 1 (3D)
A549 cells were grown as 3D-culture/spheroids to 80% confluency and incubated with 10 ng/mL TNF and 2 ng/mL TGF two times each for 48 hours. Samples were taken 4 days after the treatment.
Control untreated A549 cell sample (3D)
A549 cells were grown as 3D-culture to 80% confluency and kept in culture for 4 days.

MCF-7:2A / MCF-7

Relative Expression (log2-ratio):-1.456748
Number of Samples:4 / 4
Experimental MCF-7:2A
Long-term estrogen deprived breast cancer cells MCF-7, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. MCF-7 is human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Parental cell line:: MCF-7 Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

MCF-7.5C / MCF-7

Relative Expression (log2-ratio):-1.3550911
Number of Samples:3 / 4
Experimental MCF-7.5C
Human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Long-term estrogen deprived breast cancer cells, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. Parental cell line:: MCF-7 Synonyms:MCF-7 clone 5C; 5C; MCF-7:5C Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):-1.328435
Number of Samples:5 / 17
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons.

DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) / DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)

Relative Expression (log2-ratio):1.253808
Number of Samples:55 / 39
Experimental DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.

DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):-1.2512732
Number of Samples:16 / 33
Experimental DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.